|
TMCC3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
2.162300E-02 |
| Normal-vs-Stage3 |
1.9364509995512E-12 |
| Normal-vs-Stage4 |
9.46689999725692E-08 |
| Stage1-vs-Stage2 |
1.721610E-02 |
| Stage1-vs-Stage3 |
2.096200E-01 |
| Stage1-vs-Stage4 |
7.978600E-01 |
| Stage2-vs-Stage3 |
1.779040E-03 |
| Stage2-vs-Stage4 |
1.827770E-02 |
| Stage3-vs-Stage4 |
4.990400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.829150E-04 |
| Normal-vs-Asian |
4.22789999999784E-05 |
| Caucasian-vs-AfricanAmerican |
2.465400E-01 |
| Caucasian-vs-Asian |
2.487800E-01 |
| AfricanAmerican-vs-Asian |
8.969900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.21999998781553E-10 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.278000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(41-60Yrs) |
1.62914126633495E-12 |
| Normal-vs-Age(61-80Yrs) |
4.28500000004828E-06 |
| Normal-vs-Age(81-100Yrs) |
1.490390E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.055010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.678500E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.569900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.107380E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.659800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.415800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.442040E-02 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
3.172200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.91919829922927E-11 |
| Tall-VS-Other |
1.956090E-02 |
| Tall-VS-Normal |
1.27570176644554E-11 |
| Follicular-VS-Other |
2.996200E-01 |
| Follicular-VS-Normal |
4.945000E-01 |
| Other-VS-Normal |
2.458800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.55269999582808E-08 |
| Normal-vs-N1 |
3.52090000488303E-08 |
| N0-vs-N1 |
3.557100E-03 |
|
|
